Galapagos, a biotech company, has bought CellPoint, a cell therapy company, from +ND Capital.
The deal will accelerate the development and commercialization of CellPoint’s CAR-T delivery model.
Tol Trimborn, CEO of CellPoint, said, “We could not have reached today’s milestone without the commitment and management expertise of our sole investor, +ND Capital. Despite the progress with current CAR-T therapies, long lead times, highly manual central manufacturing, and complex logistics remain the limiting factors for large-scale capacity and broad patient access. We are excited to become part of Galapagos to realize the potential of our innovative CAR-T delivery model.”